publicaciones seleccionadas
-
documento
- Enalapril‐induced angioedema: A forgotten adverse event 2022-06
- News on angiotensin II and atrial fibrillation : from the molecular to the pathophysiological. 2021-04-15
- Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure 2021-01-14
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure 2020-10-08
- La pandemia : virtualidad en la educación. 2020-07-01
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome 2015-12-03
- Manifestaciones cardiovasculares de anemia de células falciformes 2015-07
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes 2015-06-18
- Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction 2015-05-07
- Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo 2015-05
- Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure 2015-01-06
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure 2014-09-11
- Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome 2014-09-10
- Consenso latino-americano de hipertensão em pacientes com diabetes tipo 2 e síndrome metabólica 2014-04
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation 2013-11-28
- Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF) 2013-09
- I-ADD Study: Assessment of Efficacy and Safety Profile of Irbesartan/Amlodipine Fixed-Dose Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled With Irbesartan 150 mg Monotherapy: A Multicenter, Phase III, Prospective, Randomized, Open-Label With Blinded–End Point Evaluation Study 2012-08
- Heart Rate and Use of Beta-Blockers in Stable Outpatients with Coronary Artery Disease 2012-05-03
- Vorapaxar in the Secondary Prevention of Atherothrombotic Events 2012-04-12
- Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial 2012-01
- RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome 2011-10